Wildenbeest, Joanne G;
van den Broek, Peterhans J;
Benschop, Kimberley SM;
Koen, Gerrit;
Wierenga, Peter C;
Vossen, Ann CTM;
Kuijpers, Taco W;
Wolthers, Katja C
Pleconaril Revisited: Clinical Course of Chronic Enteroviral Meningoencephalitis after Treatment Correlates with In Vitro Susceptibility
You can manage bookmarks using lists, please log in to your user account for this.
Media type:
E-Article
Title:
Pleconaril Revisited: Clinical Course of Chronic Enteroviral Meningoencephalitis after Treatment Correlates with In Vitro Susceptibility
Contributor:
Wildenbeest, Joanne G;
van den Broek, Peterhans J;
Benschop, Kimberley SM;
Koen, Gerrit;
Wierenga, Peter C;
Vossen, Ann CTM;
Kuijpers, Taco W;
Wolthers, Katja C
Published:
SAGE Publications, 2012
Published in:
Antiviral Therapy, 17 (2012) 3, Seite 459-466
Language:
English
DOI:
10.3851/imp1936
ISSN:
1359-6535;
2040-2058
Origination:
Footnote:
Description:
Background Human enteroviruses (HEVs) can cause severe infections, especially in patients with a deficient humoral immune response, such as X-linked agammaglobulinemia. In this patient group, chronic enteroviral meningitis (CEMA) is feared because of extensive morbidity and high fatality rate. Treatment options consist of intravenous immunoglobulin (IVIG), with various outcomes. Pleconaril is an antiviral agent with in vitro activity against HEVs that has been used in the treatment of HEV infections. Methods The efficacy of pleconaril and IVIG against HEV isolated from the patients was assessed in vitro in two patients with CEMA. Results Echovirus 11 was found in the cerebrospinal fluid (CSF) of case 1. Treatment with high-dose IVIG and pleconaril did not provide any clinical improvement and HEV PCR in CSF remained positive. Case 2 (echovirus 13 positive in CSF) was also treated with IVIG and pleconaril. The patient recovered completely and HEV PCR in CSF became negative. Recent IVIG batches contained low titres of neutralizing antibodies against the patient strains. Echovirus 11 (case 1) was resistant to pleconaril in vitro, whereas echovirus 13 (case 2) was susceptible, in accordance with virological response after treatment and subsequent clinical results. Conclusions This is the first report that evaluates efficacy of antiviral treatment in CEMA patients in relation to in vitro susceptibility of clinical virus isolates. Since pleconaril is no longer available for compassionate use we strongly propagate that new drugs should be developed against these potential life threatening HEV infections.